Illness Risk Following Rapid Versus Gradual Discontinuation of Antidepressants
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Rapid discontinuation of some psychotropic medications is followed by discontinuation symptoms as well as an increased risk of early illness recurrence. Recurrence occurs earlier after rapid than after gradual discontinuation with lithium and antipsychotics. The authors compared illness recurrence after rapid versus gradual discontinuation of antidepressants. METHOD: The authors compared 398 patients with a DSM-IV diagnosis of recurrent major depressive disorder (N=224), panic disorder (N=75), bipolar II disorder (N=62), or bipolar I disorder (N=37). Two-thirds were women, the mean age was 42 years, and patients were treated with antidepressants for a mean of 8.5 months. Antidepressants were discontinued clinically, either rapidly (over 1-7 days; N=188) or gradually (over 14 days or more; N=210), with a mean follow-up duration of 2.8 years; patients who were ill at discontinuation were excluded from the analysis. The authors compared latency to first new illness episodes using survival analysis and Cox multivariate modeling. RESULTS: The latency to first illness with rapid discontinuation was 0.4 times that with gradual discontinuation, and the latency after rapid discontinuation was one-fourth the estimated average previous interepisode interval in the same patients. The effect was similar across antidepressant classes and across years; the pace of discontinuation had less effect with drugs of prolonged half-life. The effect also varied by diagnosis (bipolar I > or = panic > bipolar II > or = major depressive disorder) but not by episodes per year, duration of index illness, use of concomitant treatment, or antidepressant dose or duration. CONCLUSIONS: The recurrence risk for depression or panic was much shorter after rapid than after gradual discontinuation of antidepressants. These findings have implications for both clinical management and the design and interpretation of clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One study found that tapering over 4 weeks was not feasible, with most (60%) patients tapering their medications over 4 months 41 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [41]
In the citing paper
“Indeed, even reductions from 2•5 mg (a quarter of the smallest available tablet) to 0mg will produce a reduction in SERT inhibition of 42•9%, and reduction from 1•25mg (an eighth of a tablet) to 0mg will produce a 28% reduction (larger than the change from 40mg to 5mg (27•3%)), perhaps accounting for the lack of success of previous tapering regimes 41,42 , and particularly for the difficulties”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [41]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Cohen, L. S. (2006) · JAMA · doi:10.1001/jama.295.5.499 · Cited by 1,031
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
THE TREATMENT OF DEPRESSIVE STATES WITH G 22355 (IMIPRAMINE HYDROCHLORIDE)
KUHN, R. (1958) · American Journal of Psychiatry · doi:10.1176/ajp.115.5.459 · Cited by 615
Viguera, A. C., Nonacs, R., Cohen, L. S., Tondo, L., Murray, A., & Baldessarini, R. J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.2.179 · Cited by 488
Self-citationRisk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder
Suppes, T. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810360046007 · Cited by 392
Study of Compulsive Buying in Depressed Patients
Lejoyeux, M., Tassain, V., Solomon, J., & AdAs, J. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0406 · Cited by 271
Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
Viguera, A. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130055011 · Cited by 246
Outcome After Rapid vs Gradual Discontinuation of Lithium Treatment in Bipolar Disorders
Faedda, G. L. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820180046005 · Cited by 239
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214
Research works printed but not linked: 6
- National Center for Health Statistics, 2007, Health United States–2007, 333
- Schatzberg AR, 1997, J Clin Psychiatry, 58, 23
- Duenwald M, 2004, New York Times, D1
- Schatzberg AF, 2006, J Clin Psychiatry, 67, 27
- 10.1177/0269881107081550 · doi:10.1177/0269881107081550 · Paper page
- Baldessarini RJ : Drug therapy of depression and anxiety disorders, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th ed . Edited by , Brunton LL , Lazo JS , Parker KL. New York, McGraw-Hill, 2005, pp 429–459
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
“5 times more quickly when discontinuation was rapid versus gradual (355).”
BackgroundCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
“The optimum rate to taper drug dose is unknown, with opinions varying from a few weeks to a year (Greden, 1993); however, a case-note review of nearly 400 patients followed-up for an average of nearly 3 years suggest that the risk of relapse into a new episode of illness is higher following rapid (1–7 day) versus grad…”
BackgroundBaldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Self-citationTapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Episodes of Mood Disorders in 2,252 Pregnancies and Postpartum Periods
Viguera, A. C., Tondo, L., Koukopoulos, A. E., Reginaldi, D., Lepri, B., & Baldessarini, R. J. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010148 · Cited by 279
Pharmacological treatment of adult bipolar disorder
Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0044-2 · Cited by 272
Undurraga, J., & Baldessarini, R. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.306 · Cited by 269
Bipolar depression: a major unsolved challenge
Baldessarini, R. J., Vázquez, G. H., & Tondo, L. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0160-1 · Cited by 235
Self-citationSim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
“Such treatment-discontinuation, itself, may contribute to inferior outcomes in placebo-arms of trials, especially if treatment-discontinuation is abrupt or rapid (Baldessarini et al., 2010; Baldessarini, 2013; Baldessarini et al., 2015).”
BackgroundBoot, B. P., Boeve, B. F., Roberts, R. O., Ferman, T. J., Geda, Y. E., Pankratz, V. S., Ivnik, R. J., Smith, G. E., McDade, E., H. Christianson, T. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22655 · Cited by 197
A review of the management of antidepressant discontinuation symptoms
Wilson, E., & Lader, M. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315612334 · Cited by 103
“They also add that illness latency after discontinuing antidepressants was not related to duration of treatment or dose [Baldessarini et al. 2010].”
BackgroundOverview of antidepressant treatment of bipolar depression
Vázquez, G. H., Tondo, L., Undurraga, J., & Baldessarini, R. J. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000023 · Cited by 94
“Antidepressants in bipolar depression 1677 D ow nloaded from https://academ ic.oup.com /ijnp/article-abstract/16/7/1673/713713 by guest on 16 O ctober 2019 Goldberg et al., 2007 ; Sachs et al., 2007 ; Ghaemi et al., 2008, 2010 ; Baldessarini et al., 2010d; Frye et al., 2011).”
BackgroundMethodInfluentialEsketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Managing antidepressant discontinuation: a systematic review
Maund, E., Stuart, B., Moore, M., Dowrick, C., Geraghty, A. W. A., Dawson, S., & Kendrick, T. (2019) · The Annals of Family Medicine · doi:10.1370/afm.2336 · Cited by 82
“in one, inclusion criteria stated patients had to remain euthymic for one week after discontinuation.(53)”
BackgroundInfluentialTondo, L., Baldessarini, R. J., Vázquez, G., Lepri, B., & Visioli, C. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12023 · Cited by 79
Hengartner, M. P. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320921694 · Cited by 72
Morbidity in depressive disorders
Baldessarini, R. J., Forte, A., Selle, V., Sim, K., Tondo, L., Undurraga, J., & Vázquez, G. H. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000448661 · Cited by 63
New insights on the antidepressant discontinuation syndrome
Harvey, B. H., & Slabbert, F. N. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2429 · Cited by 58
“Over the long term, ADS can reduce the time between depressive episodes and significantly increase the risk of new episodes (Baldessarini et al., 2010).”
BackgroundInfluentialDuration of Initial Antidepressant Treatment and Subsequent Relapse of Major Depression
Baldessarini, R. J., Lau, W. K., Sim, J., Sum, M. Y., & Sim, K. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000263 · Cited by 52
“The present findings are not surprising, given the natural history of untreated major depressive episodes, which require a median of perhaps 12 months to recover spontaneously.(2,5,6) Indeed, the term relapse is probably appropriate for new or worsening illness arising within 12 months of the start of an acute depress…”
BackgroundEffects of Treatment Discontinuation in Clinical Psychopharmacology
Baldessarini, R. J., & Tondo, L. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000497334 · Cited by 52
Self-citationHengartner, M. P. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00275 · Cited by 52
“In support of this notion, it has been shown that rapid discontinuation of antidepressants, relative to gradual tapering, prospectively increases the risk of depression reoccurrence (64), but note that even very slow tapering may cause severe mood disturbances (61, 63).”
BackgroundTsai, A. C., Rosenlicht, N. Z., Jureidini, J. N., Parry, P. I., Spielmans, G. I., & Healy, D. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000434 · Cited by 43
“This ‘‘bipolar rebound phenomenon’’ has been most often described for lithium, but it has also been observed in the setting of abruptly withdrawn antiepileptic [78], antipsychotic [3,12,48,56, 78–80], and antidepressant medications [59,75,78,81] administered to persons diagnosed with other mood and psychotic disorders.”
Perinatal anxiety: approach to diagnosis and management in the obstetric setting
Thorsness, K. R., Watson, C., & LaRusso, E. M. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.05.017 · Cited by 51
(2010) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20100730-04 · Cited by 38
Studies of Long-Term Use of Antidepressants: How Should the Data from Them be Interpreted?
El-Mallakh, R. S., & Briscoe, B. (2012) · CNS Drugs · doi:10.2165/11599450-000000000-00000 · Cited by 36
Roman, M. W. (2012) · Issues in Mental Health Nursing · doi:10.3109/01612840.2012.713447 · Cited by 36
Outcome of antidepressant drug discontinuation with taperingstrips after 1–5 years
Groot, P. C., & van Os, J. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320954609 · Cited by 35
Potential Adverse Effects of Discontinuing Psychotropic Drugs: Part 2: Antidepressant Drugs
(2010) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20100527-98 · Cited by 35
International Consensus Group on Depression Prevention in Bipolar Disorder
Frye, M. A., Ha, K., Kanba, S., Kato, T., McElroy, S. L., Özerdem, A., Vázquez, G., & Vieta, E. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10123co1c · Cited by 31
Increased Frequency of First-Episode Poststroke Depression After Discontinuation of Escitalopram
Mikami, K., Jorge, R. E., Moser, D. J., Arndt, S. V., Jang, M., Solodkin, A., Small, S. L., Fonzetti, P., Hegel, M. T., & Robinson, R. G. (2011) · Stroke · doi:10.1161/strokeaha.111.626507 · Cited by 30
Cohen, D., & Recalt, A. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496733 · Cited by 28
Antidepressant discontinuation syndrome: A state-of-the-art clinical review
Fornaro, M., Cattaneo, C. I., Berardis, D. D., Ressico, F. V., Martinotti, G., & Vieta, E. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.10.005 · Cited by 35
Discontinuing psychotropic drug treatment
Tondo, L., & Baldessarini, R. J. (2020) · BJPsych Open · doi:10.1192/bjo.2020.6 · Cited by 27
The Impact of Psychopharmacology on Contemporary Psychiatry
Baldessarini, R. J. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405900801 · Cited by 42
Prevention of Poststroke Mortality Using Problem-Solving Therapy or Escitalopram
Robinson, R. G., Jorge, R. E., & Long, J. D. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.10.001 · Cited by 25
Inada, K., Enomoto, M., Yamato, K., Marumoto, T., Takeshima, M., & Mishima, K. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.040 · Cited by 26
Shapiro, B. B. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4995-4 · Cited by 20
Choe, C. J., Emslie, G. J., & Mayes, T. L. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.07.002 · Cited by 26
Baldessarini, R. J., Lau, W. K., Sim, J. Z. T., Sum, M. Y., & Sim, K. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw092 · Cited by 20
“The greater observed risks associated with antidepressant treatment are particularly surprising in view of the greater risk of depressive relapses of recurrences in placebo arms of the reported trials and the adverse effects of antidepressant discontinuation (Baldessarini et al., 2010, 2015).”
BackgroundLiu, X., Momen, N. C., Molenaar, N. M., Rommel, A., Bergink, V., & Munk‐Olsen, T. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.04.045 · Cited by 24
Vilhelmsson, A., Svensson, T., Meeuwisse, A., & Carlsten, A. (2012) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-13-19 · Cited by 18
“Research has shown that antidepressant discontinuation in depressed patients can be associated with worsened depression and increased suicidality [22], and that the recurrence risk for depression was much shorter after rapid than after gradual discontinuation of antidepressants [23].”
BackgroundTapering antidepressants: is 3 months slow enough?
Phelps, J. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.08.035 · Cited by 16
“This was strongly suggested in a recent study in which taper rates less than 14 days were associated with much more rapid relapse than tapers over a longer period, whether the diagnosis was depression or bipolar disorder or panic [6].”
ResultRisk factors for early recurrence after discontinuing lithium in bipolar disorder
Baldessarini, R. J., Pinna, M., Contu, M., Vázquez, G. H., & Tondo, L. (2022) · Bipolar Disorders · doi:10.1111/bdi.13206 · Cited by 18
Antidepressant dosage taken by patients with bipolar disorder: factors associated with irregularity
Bauer, R., Glenn, T., Alda, M., Sagduyu, K., Marsh, W., Grof, P., MUNOZ, R. A., Murray, G., Ritter, P. S., Lewitzka, U., et al. (2013) · International Journal of Bipolar Disorders · doi:10.1186/2194-7511-1-26 · Cited by 17
“In addition to immediate symptoms related to drug half-lives, late-appearing symptoms related to longterm adaptive responses to cerebral pharmacodynamic effects may also occur (Baldessarini 1995; Baldessarini et al. 2010; Osterberg et al. 2010).”
BackgroundAbrupt Withdrawal of Antidepressant Treatment
Freedman, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10050783 · Cited by 17
Huijbers, M. J., Wentink, C., Simons, E. M. F., Spijker, J., & Speckens, A. E. M. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-039053 · Cited by 17
Overview of Antidepressant Treatment of Bipolar Depression
Vázquez, G. H., Tondo, L., Undurraga, J. P., & Baldessarini, R. J. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.130119 · Cited by 15
Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models
Zabegalov, K. N., Kolesnikova, T. O., Khatsko, S. L., Volgin, A. D., Yakovlev, O. A., Amstislavskaya, T. G., Alekseeva, P. A., Мешалкина, Д. А., Friend, A. J., Bao, W., et al. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.04.003 · Cited by 15
A Pill for the Ill? Depression, Medicalization and Public Health.
Vilhelmsson, A. (2014) · Socialmedicinsk tidskrift · doi:10.62607/smt.v91i1.43076 · Cited by 14
“Research, however, has shown that antidepressant discontinuation in depressed patients can be associated with worsened depression and increased suicidality [252], and that the recurrence risk for depression was much shorter after rapid cessation than after gradual discontinuation of antidepressants [253].”
Wentink, C., Huijbers, M. J., Lucassen, P. L., Kramers, C., Akkermans, R., Adang, E., Spijker, J., & Speckens, A. E. M. (2019) · BMC Family Practice · doi:10.1186/s12875-019-0989-5 · Cited by 15
Pharmacological treatment of bipolar depression
Vázquez, G. H., Tondo, L., Undurraga, J. P., Zaratiegui, R. M., Selle, V., & Baldessarini, R. J. (2014) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.113.011460 · Cited by 13
Predictors of successful discontinuation of antipsychotics and antidepressants
Lincoln, T. M., Sommer, D., Quazzola, M., Witzgall, T., & Schlier, B. (2021) · Psychological Medicine · doi:10.1017/s0033291721005146 · Cited by 13
“Given that this finding does not align with clinical observations and previous research that indicates gradual withdrawal to be advantageous (Baldessarini et al., 2010; Groot & van Os, 2020) the limitations of the non-randomized design and the putative interaction effects noted above require particular attention.”
ResultAntidepressant Discontinuation Syndrome
Kim, S. H., Kim, Y. S., & Kang, U. G. (2024) · 신경정신의학 · doi:10.4306/jknpa.2024.63.2.104 · Cited by 12
Scholten, W., Batelaan, N. M., van Oppen, P., Smit, J. H., & van Balkom, A. J. L. M. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000350450 · Cited by 12
Interventions to help patients withdraw from depression drugs: A systematic review
Gøtzsche, P. C., & Demasi, M. (2023) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-230011 · Cited by 15
Pharmacological treatment of bipolar disorder in pregnancy
Singh, S., & Deep, R. (2022) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_407_21 · Cited by 10
“[10] Pregnancy is not protective for relapse of BD and postpartum risk increases further.”
Meißner, C., Warren, C. V., Fadai, T., Müller, A., Zapf, A., Lezius, S., Ozga, A., Falkenberg, I., Kircher, T. T. J., & Nestoriuc, Y. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04941-3 · Cited by 11
“Yet, with no safe and effective discontinuation rationale established, these patients face multiple challenges [25–28]: Patients are not routinely informed about timelines and methods for discontinuation, leading to abrupt or unsupervised attempts, unsafe tapering regimens, or refraining from discontinuation at all [2…”
BackgroundSaastamoinen, L., Wallin, M., Lavikainen, P., Airaksinen, M., Sourander, A., & Bell, J. S. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1233-6 · Cited by 10
International Report: Local response following the Great East Japan Earthquake 2011
Meguro, K. (2011) · Neurology · doi:10.1212/wnl.0b013e31822511a5 · Cited by 9
Lithium-discontinuation-induced treatment refractoriness revisited
Kupka, R., Regeer, E. J., van Bergen, A., Tondo, L., & Bauer, M. (2024) · International Journal of Bipolar Disorders · doi:10.1186/s40345-024-00339-6 · Cited by 8
Helping people to discontinue antipsychotics: if, when and how
Moncrieff, J., & Horowitz, M. A. (2025) · Schizophrenia · doi:10.1038/s41537-025-00695-x · Cited by 11
“Finally, the association between slower discontinuation and lower relapse risk has been shown for other psychiatric drugs in other conditions 50,51 .”
Psilocybin as a disease-modifying drug—a salutogenic approach in psychiatry
Spangemacher, M., Mertens, L. J., Färber, L. V., Jungaberle, A., Jungaberle, H., & Gründer, G. (2024) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0224 · Cited by 12
Differing antidepressant maintenance methodologies
Safer, D. J. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.07.021 · Cited by 9
“Tapering over a two week period somewhat reduces ADM relapse rates [122], although a longer ADM taper (up to 3 months or more) produces lower relapse rates [99,123–125].”
BackgroundWu, R., Kemp, D. E., Sajatovic, M., Zhao, J., Calabrese, J. R., & Gao, K. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.013 · Cited by 6
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Unmet Needs in Psychiatry: Bipolar Depression
Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-42637-8_4 · Cited by 8
Baldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_3 · Cited by 9
Risks in Discontinuation Trials With Antidepressants
Baldessarini, R. J. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14lr09255 · Cited by 4
Baldessarini, R. J., Tondo, L., Visioli, C., & Vázquez, G. H. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.10.058 · Cited by 4
“In addition, more previous episodes of depression inconsistently predicted earlier recurrence after discontinuing antidepressant treatment (Viguera et al., 1998; Baldessarini et al., 2010).”
BackgroundIllness Risk Following Rapid Versus Gradual Discontinuation of Antidepressants
Ballenger, J. C. (2011) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/j.ypsy.2010.10.028 · Cited by 4
Aggestrup, A. S., Martiny, F., Faurholt‐Jepsen, M., Hvenegaard, M., Christensen, R., Davidsen, A. S., & Martiny, K. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291559 · Cited by 4
Comentario: el estado actual de la psicofarmacología y la psiquiatría
Baldessarini, R. J. (2011) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2011.03.001 · Cited by 4
Moncrieff, J., Jakobsen, J. C., & Bachmann, M. O. (2021) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2021-111743 · Cited by 4
Kassm, S. A., & Naja, W. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.080 · Cited by 3
Transitioning Concussion Care to Mental Health Care: A Case Study of an Elite Athlete
Sherry, N. S., Feder, A. H., Pan, R. J., Eagle, S. R., & Kontos, A. P. (2021) · Case Studies in Sport and Exercise Psychology · doi:10.1123/cssep.2021-0015 · Cited by 4
Müller, A., Konigorski, S., Meißner, C., Fadai, T., Warren, C. V., Falkenberg, I., Kircher, T. T. J., & Nestoriuc, Y. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05184-y · Cited by 4
Deprescripción de medicamentos
Moral, E. G., Bueno, M. B., Hernández, J. M. G., Herrero, J. V., de Gracia, L. J., Barroso, A. V., & Moral, E. G. (2015) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2015.06.004 · Cited by 4
Kuśmider, M., Faron‐Górecka, A., Pabian, P., Solich, J., Szlachta, M., Kolasa, M., Żurawek, D., Wójcikowski, J., Daniel, W. A., & Dziedzicka‐Wasylewska, M. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.11.016 · Cited by 3
“However, rapid antidepressant discontinuation has been shown to remain associated with a shorter time to the next recurrent depressive episode (Viguera et al., 1998; Baldessarini et al., 2010).”
LaRusso, E. M., & Freeman, M. P. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-386007-1.00018-0 · Cited by 3
Aggestrup, A. S., Martiny, F., Henriksen, L., Davidsen, A. S., & Martiny, K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302229 · Cited by 2
Aggestrup, A. S., Martiny, K., & Davidsen, A. S. (2025) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2025.2530628 · Cited by 2
Scientific basis of the homeopathic healing principle in modern pharmacology
Teixeira, M. Z. (2017) · Revista de Homeopatia · Cited by 10
Swann, A. C. (2013) · Bipolar Disorders · doi:10.1111/bdi.12037 · Cited by 2
Können Antidepressiva den langfristigen Verlauf depressiver Erkrankungen negativ verändern?
Gründer, G., Mertens, L. J., Spangemacher, M., & Schmitz, C. N. (2025) · Der Nervenarzt · doi:10.1007/s00115-025-01801-1 · Cited by 1
Majkic, N., & Taylor, D. M. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251364388 · Cited by 3
“Abruptly stopping antidepressants at any time worsens the risk of relapse (Baldessarini et al., 2010), although withdrawal symptoms may inflate the measured risk of relapse (Horowitz and Taylor, 2022).”
Horowitz, M. A. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf256 · Cited by 1
Antidepressant-Antianxiety Agents
Baldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_4 · Cited by 1
Commentary: The current state of psychopharmacology and psychiatry
Baldessarini, R. J. (2011) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/s2173-5050(11)70002-4 · Cited by 2
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Aggestrup, A. S., Martiny, F., Faurholt‐Jepsen, M., Hvenegaard, M., Christensen, R., Davidsen, A. S., & Martiny, K. (2022) · medRxiv · doi:10.1101/2022.10.06.22280499 · Cited by 1
In the system for too long: former foster youth and the structural ambivalence towards mental health
Baiocchi, A. (2014) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 1
Schwertfeger, N., Regen, F., Szegedi, A., & Benkert, O. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_76
Rapid discontinuation of antidepressants reduces time to recurrence of depression and panic
Furukawa, T. A. (2011) · Evidence-Based Mental Health · doi:10.1136/ebmh.14.1.13
Bibliography D EPRESSION A ND D YSTHYMIA
Rj, A., Ma, F., Oa, A., Kh, L., Pe, H., Filkowski, M. M., Cuijpers, P. M. H., Markowitz, J. C., Hansen, R. A., Thieda, P., et al. (2012)
Individualized Treatment of Depression
(2013) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814343664_0010
The Role of Antiepileptic Drugs in Bipolar Depression
Molina, J. D. D., Durán, M., Lopez-Munoz, F. J., Álamo, C., & Toledo-Romero, F. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_50
Rapid vs. Gradual Discontinuation of Antidepressants
Yager, J. (2010) · Journal watch · doi:10.1056/jp201009030000001
McLaughlin, P., & Cleare, A. J. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.009
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg002
Metadata
- Authors
- Baldessarini, R. J., Tondo, L., Ghiani, C., & Lepri, B.
- Affiliations
- Harvard University (US)
- Venue
- American Journal of Psychiatry
- Published
- 2010-08-01
- Volume
- 167
- Issue
- 8
- Pages
- 934-941
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2170925735
- Cited by
- 123
- References
- 35
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 12 · 2023: 5 · 2022: 4 · 2021: 7 · 2020: 8 · 2019: 5 · 2018: 6 · 2017: 5 · 2016: 3 · 2015: 6 · 2014: 7 · 2013: 5 · 2012: 16
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r03mh073579-02)
- National Institute of Mental Health (MH-073579)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- antidepressant discontinuation, major depressive disorder, panic disorder, bipolar disorder, discontinuation symptoms
- MeSH terms
- Adult, Antidepressive Agents, Bipolar Disorder, Major Depressive Disorder, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Risk Factors, Substance Withdrawal Syndrome, Time Factors, Proportional Hazards Models, Survival Analysis, Panic Disorder, Treatment Outcome, Risk Assessment, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.